The Health Effects of Cannabis – Informed Opinions

Enter any pub or public place and canvass opinions on cannabis and there will be a different view for each person canvassed. Some remarks will be educated from sources while some will be formed upon no foundation. To be sure, research and conclusions based on the study are tough given the history of illegality. Nevertheless, there’s a groundswell of opinion that cannabis is good and must be legalized. The path has been taken by many States in Australia and America. Countries are following suit or contemplating options. So what is the position now? Is it?

The National Academy of Sciences published a 487-page report that this season (NAP Report) on the current state of evidence for the subject matter. Many authorities grants affirmed this committee, a collection of 16 professors’ work. They have been supported by 15 academic reviewers along with some 700 relevant books considered. The report is viewed as state of the art on recreational use in addition to medical. This article draws heavily on this source.

The expression cannabis is used broadly here to represent cannabis and marijuana, the latter being mined from a different part of the plant. More than 100 chemical compounds are found in cannabis, each offering distinct benefits or threat. See: Safety Culture Works Program | Safety Culture Improvement & Tools


A person who can be”benign” on smoking cannabis may experience a euphoric state in which time is irrelevant, music and colors take on a greater significance and the individual might acquire the”nibblies”, needing to eat fatty and sweet foods. This is frequently related to comprehension and motor skills. When high blood clots have been attained, paranoid thoughts, hallucinations, and panic attacks may describe his”trip”. Visit us at Safety Culture Works.


In the vernacular, cannabis is often characterized as”good shit” and”bad shit”, reverted to widespread contamination clinic. The contaminants can come from soil quality (eg pesticides & heavy metals) or add afterward. Occasionally particles of beads of glass augment the fat sold.


  • A random choice of therapeutic effects seems here in the context of their evidence standing. A few of the outcomes will be revealed beneficial, but some carry danger. Some consequences are distinguished from the placebos of this research.
  • Cannabis in the treatment of epilepsy is inconclusive on account of inadequate evidence.
  • Nausea and vomiting caused by chemotherapy can also be ameliorated by oral cannabis.
  • A reduction in the intensity of pain in patients with chronic pain is a likely outcome for the use of cannabis.
  • Spasticity in Multiple Sclerosis (MS) patients have been reported as developments in symptoms.
  • Increase in appetite and decline in weight reduction in HIV/ADS sufferers has been proven in limited signs.
  • Based on restricted signs, cannabis is ineffective in treating glaucoma.
  • On the basis of limited evidence, cannabis is effective in treating Tourette syndrome.
  • The celiac disease was aided by cannabis in one documented trial.
  • Limited statistical evidence points to enhance outcomes for traumatic brain injury.
  • There is inadequate evidence to claim that cannabis can help Parkinson’s disease.
  • Limited evidence dashed hopes that cannabis might help improve the symptoms of dementia victims.
  • Limited statistical evidence can be found to support an association between smoking cannabis and heart attack.
  • On the basis of limited evidence, cannabis is ineffective to treat depression
  • The evidence for a reduced risk of metabolic problems (diabetes etc) is restricted and statistical.
  • Social anxiety disorders can be helped by cannabis, although the evidence is limited. Asthma and cannabis usage isn’t well supported by the evidence either against or for.
  • The celiac disease was helped by cannabis in one reported trial.
  • A conclusion that cannabis will help schizophrenia victims cannot be supported or refuted on the grounds of their limited nature of the signs.
  • There is moderate evidence that greater short-term sleeping results for disturbed sleep individuals.
  • Alcoholism and smoking cannabis are correlated with the reduced birth weight of the baby.
  • The signs for stroke brought on by cannabis use is restricted and statistical.
  • Addiction to cannabis and gateway problems are complicated, taking into account many variables that are beyond the scope of this report. These issues are fully discussed at the NAP report. Click here to get started!


The NAP report highlights the following findings on the issue of cancer:

  • The evidence suggests that smoking cannabis does not increase the risk for specific cancers (i.e., lung, head and neck) in adults.
  • There is little evidence that cannabis use is associated with a single subtype of esophageal cancer.
  • There is minimal evidence that parental cannabis use during pregnancy is related to increased cancer risk in offspring.
  • The NAP report highlights the following findings on the issue of respiratory ailments:
  • Smoking cannabis on a regular basis is related to a chronic cough and phlegm production.
  • Quitting cannabis smoking is likely to reduce a chronic cough and phlegm production.
  • It is uncertain whether cannabis use is associated with the chronic obstructive pulmonary disease, asthma, or worsened lung function.


The NAP report highlights the following findings on the issue of the human immune system:

  • There exists a paucity of data on the effects of cannabis or cannabinoid-based therapeutics on the human immune system.
  • There’s inadequate data to draw philosophical conclusions regarding the effects of cannabis smoke or cannabinoids on immune competence.
  • There is limited evidence to suggest that routine exposure to cannabis smoke could have anti-inflammatory action.
  • There is inadequate evidence to support or refute a statistical association between cannabis or cannabinoid use and adverse effects on immune status in people with HIV.


The NAP report highlights the following findings on the Dilemma of the increased risk of death or injury:

  • Cannabis use before driving increases the possibility of being involved in a motor vehicle accident.
  • In nations where cannabis use is legal, there’s an elevated risk of unintentional cannabis overdose injuries among kids.
  • It is uncertain if and how cannabis use is related to all-cause mortality or with an occupational injury.


The NAP report highlights the following findings on the issue of cognitive performance and mental health:

  • Present cannabis use impairs the operation in cognitive domains of learning, memory, and focus. Recent use may be described as cannabis usage.
  • A limited number of research suggest there are impairments in cognitive domains of learning, memory, and attention in individuals who have stopped smoking cannabis.
  • Cannabis use during adolescence is related to impairments in following academic achievement and education, employment and income, and social relationships and social functions.
  • Cannabis use is very likely to boost the risk of developing schizophrenia and other psychoses; the greater the usage, the larger the risk.
  • In individuals with schizophrenia and other psychoses, a history of cannabis use may be linked to improved performance on memory and learning activities.
  • Cannabis use doesn’t appear to increase the probability of developing depression, anxiety, and posttraumatic stress disorder.
  • For individuals diagnosed with prostate disorders, near-daily cannabis use could be linked to greater symptoms of bipolar disorder than for nonusers.
  • Heavy cannabis users are more inclined to report thoughts of suicide than are nonusers.
  • Regular cannabis use is very likely to increase the risk of developing a social anxiety disorder.

It has to be reasonably clear from the foregoing that cannabis isn’t the magic bullet for all health problems that some good-intentioned but ill-advised advocates of cannabis would have us think. Nevertheless, the product offers much hope. Solid research can help to clarify the problems. The NAP report is a step in the ideal direction. There are still many barriers to exploring this drug that is amazing. In time the benefits and dangers will be fully understood. Confidence in the product will increase and a number of the barriers, social and academic, will drop by the wayside.